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Imaging Markers of Isocitrate Dehydrogenase-1
Mutations in Gliomas
G
lioblastomas (GBM) are the commonest
and most aggressive primary tumor of the
brain. They are associated with an appall-
ing prognosis, with survival of a matter of weeks
in untreated patients, improving to 14 to 16
months with radiotherapy with concomitant and
adjuvant chemotherapy.1,2 In this era of molec-
ular biology, diagnosis still relies on the World
Health Organization classification system, which
only requires a tumor to have features of an
astrocytic tumor with either necrosis or micro-
vascular proliferation on light microscopy.3 Yet,
it is clear that GBMs form a very heterogeneous
group of tumors. Although there are recognized
histological variants (eg, giant-cell GBM, GBM
with oligodendroglial differentiation), it is
doubtful how useful this distinction is in pre-
dicting outcome.4 It is clear that we need to be
able to better subtype GBMs to consider indi-
vidualizing treatment.
We have known for some time that GBMs can
arise from 2 pathways: either as a primary de novo
GBM or as a secondary GBM from a pre-existing
low-grade glioma. These 2 subtypes have differ-
ent mutations and activate different pathways
within the cells.5 The discovery of mutations of
the isocitrate dehydrogenase (IDH) gene, an
early marker of astrocytic tumor development,6
has led to the realization that some GBMs have
this mutation.7-9 This cohort of patients has a far
better prognosis, with a median survival of 31
months compared with 15 months in patients
with wild-type IDH.8
IDH-1 MUTATIONS IN GLIOMAS
IDH exists in 2 major forms within cells: the
cytosolic IDH-1 or the mitochondrial IDH-2. The
normal role is to convert isocitrate from the Krebs
cycle to a-ketoglutarate and in the process
replenish NADPH and NADH. a-Ketoglutarate
is also a cofactor for histone demethylase and is
involved in regulation of the genome. It is thought
thata-ketoglutarate provides a mechanism for cells
to deal with oxidative stresses (eg, that produced by
chemotherapy or radiotherapy). Mutations of the
IDH gene result in failure to synthesize
a-ketoglutarate; instead, it leads to the produc-
tion of the oncometabolite 2-hydroxyglutarate
(2-HG).10 This results in the cell being unable to
respond to oxidative stresses and may increase
sensitivity to chemotherapy and radiotherapy.
2-HG also inhibits histone demethylases and can
lead to the dysregulation of epigenetic and gene
expression. In addition, 2-HG induces the
hypoxia-inducible factor-1a subunit,11 leading
to alteration of tumor angiogenesis and growth in
low oxygen concentrations.12
Mutations of the IDH gene are found in.80%
of World Health Organization grade II and III
gliomas8 and in 12% of GBMs, mostly secondary
GBMs.7,8 In gliomas, the majority of mutations
involve IDH-1 rather than IDH-2.8 Examination
of the mutation in gliomas has shown that these
mutations are predominantly a point mutation of
histidine replacing arginine in codon 132 (R132H
mutation).6,7 This can be detectable with an
immunohistochemical test13 that is able to
identify most mutations very simply in paraffin-
embedded specimens. Recent reviews of immu-
nohistochemical diagnosis have suggested that it
can identify IDH-1 mutations with a concordance
rate to sequencing of 88% to 99%.14
If IDH-1mutations can be identified in at least
90% of cases with a simple immunohistochem-
ical test, is there a need to develop imaging
methods to do this noninvasively? There are
potential advantages:
1. IDH-1 mutation may influence surgical
decision making. A recent study by Beiko
et al15 showed that IDH-1–mutated high-
grade gliomas were more amenable to com-
plete resection of enhancing tumor and had
an improved survival with resection of the
nonenhancing components.
2. Therapeutic blockade of IDH-1. There is
much interest in developing selective inhib-
itors of the R132H IDH-1 mutation. Studies
suggest that this slows tumor growth and
promotes glioma differentiation in IDH-1–
mutated tumors but not in IDH-1 wild-type
tumors.16
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IDH-1 MUTATIONS AND CONVENTIONAL
MAGNETIC RESONANCE IMAGING
Studies comparing IDH-1 mutation status with conventional
imaging have shown some differences between IDH-1–mutated
and IDH-1 wild-type gliomas (Figure 1). IDH-1 tumors are
more commonly found in the frontal lobe,15,17-22 whereas
IDH-1 wild-type tumors commonly involve the insular
region.23 IDH-1–mutated high-grade gliomas are more likely
to be nonenhancing17,19 and in those exhibiting enhancement
may have a distinct enhancing border23 although other studies
suggest that this does not differentiate these tumors.18 In
anaplastic oligodendrogliomas, wild-type tumors are
more likely to exhibit a ring-like contrast enhancement
pattern.20
None of these features, however, are diagnostic. Carrillo et al17
have shown that combining the presence of enhancement, tumor
size, and the presence of cysts or satellite lesions can predict IDH-
1–mutated gliomas with a sensitivity of 71.4% and specificity of
99%. This needs testing prospectively.
FIGURE 1. A conventional magnetic resonance imaging (MRI) study of 2 patients. Top, the fluid-attenuated inversion-
recovery (FLAIR) image (A) and contrast-enhanced T1-weighted MRI (B) of a patient with a glioblastoma with an isocitrate
dehydrogenase-1 (IDH-1) mutation. Bottom, the tumor is located in the frontal lobe of this patient with a glioblastoma with
wild-type IDH-1, but otherwise, there are few differences between the FLAIR image (C) and contrast-enhanced T1-weighted
MRI (D).
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MEASURING 2-HG WITH MAGNETIC
RESONANCE SPECTROSCOPY
As previously mentioned, IDH-1–mutated gliomas lead to
accumulation of 2-HG within the tumor. Cell culture studies
suggest a 100-fold increase in IDH-1–mutated cells to concen-
trations of 5 to 35 mmol/L,10 a level similar to that detected with
high-resolution magic angle spectroscopy of ex vivo biopsy
specimens. A number of studies have shown that 2-HG can be
detected in ex vivo biopsy specimens with high-resolution magic
angle spectroscopy.24-27 The concordance between detecting
2-HG and IDH-1 mutation status is 86.4%.25 Detection of
2-HG identifies IDH-1 mutations with a sensitivity of 96% and
specificity of 95.2%, giving an overall accuracy of 97.8%.26
2-HG levels within these biopsy specimens increase with
increased tumor grade and increased MIB-1 proliferation rate.25
It is negatively correlated with vessel density and ADC.25 In
progressive low-grade gliomas, an increase in 2-HG can identify
glioma transformation to a higher grade.27
Recent studies have also shown that 2-HG can be detected in
patients with gliomas using single voxel magnetic resonance
spectroscopy (MRS).24,28,29 These studies suggest that it can
identify IDH-1 mutations with high sensitivity.24,28,29 Large-
scale validation studies are required to qualify this as a biomarker
of IDH-1 mutation status.
The difficulty of identifying 2-HGwith spectroscopy is that the
spectrum for 2-HG occurs between 2.6 and 2.4 ppm, a region
shared with glutamate, glutamine, and N-acetyl-L-aspartate. In
fact, the spectrum overlaps the glutamate and glutamine peaks
(Figure 2). Interestingly, the glutamate and glutamine peaks are
not affected by the IDH-1 mutation status, suggesting that the
differences are due to changes in 2-HG. Attempts using standard
short-echo MRS methods have shown a high sensitivity but low
specificity with a false-positive rate of 26%.28 Longer-echo MRS
methods that involve spectral editing and fitting the spectra to the
2-HG peak can improve the diagnostic ability29 without adding
too much complexity. More accurate and sensitive methods
include different MRS techniques in which overlapping
FIGURE 2. A short-echo magnetic resonance spectroscopy study from 2 patients with anaplastic astrocytomas. The voxels
examined in a patient with an isocitrate dehydrogenase-1 (IDH-1) mutation (A) and in a patient with a wild-type IDH-1
(B) show little differences on conventional imaging. The spectroscopic data showed that there is a detectable peak corresponding
to 2-hydroxyglutarate (2-HG) that overlaps the glutamate (Glu)/glutamine (Gln) peaks in the IDH-1–mutated patient (C).
This is not detected in the spectra of the IDH-1 wild-type patient (D). Gln, glutamine; Glu, glutamate; NAA, N-acetyl-L-
aspartate; T1-w, T1-weighted. Reproduced from Pope et al28 with permission from the publisher. Copyright © 2012 Springer
International Publishing AG.
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resonances are removed24,29 or a 2-dimensional correlation MRS
method.24 These methods have been used by some groups, but
they are not standard methods and are difficult to apply on
standard clinical machines. Overall, there is yet to be a consensus
on the best method of measuring 2-HG that balances accuracy
and ease of use to ensure that it becomes part of routine clinical
practice.
IDENTIFYING CHANGES IN MICROSTRUCTURE
WITH DIFFUSION AND DIFFUSION
TENSOR IMAGING
DiffusionMRprovidesmethods that can probe themicroscopic
physical properties of tissues and the influence of cellularity and
patterns of cellular organization. The biophysical properties of
diffusion imaging are reviewed elsewhere.30
Tan et al31 investigated the role of diffusion and diffusion
tensor methods to differentiate between IDH-1–mutated and
IDH-1 wild-type astrogliomas. They found that grade II and III
tumors have an increase in normalized apparent diffusion
coefficient (ADC) and a reduction in normalized fractional
anisotropy (FA) in the IDH-1–mutated tumors and postulated
that this was due to differences in tumor cellularity and
angiogenesis. They were able to calculate cutoff values for the
ADC and FA that provided good sensitivity and specificity for
determining the IDH-1 mutation status.
Diffusion tensor imaging has commonly been used to study the
peritumoral region. Tan et al31 found no difference in these
markers in the peritumoral regions, but previous studies have
shown that FA is an insensitive marker for identifying the invasive
margin.32 Using a tensor decomposition method splits the
information in the diffusion tensor into an isotropic component
(which measures magnitude of diffusion) and anisotropic compo-
nent (which is sensitive to directionality of diffusion).33,34 Our
previous studies have shown that these methods can identify 3
invasive phenotypes that predict the pattern of tumor progression35
and time to tumor progression.36 In a cohort of GBM patients,
virtually all of the IDH-1–mutated tumors as detected with
R132H immunohistochemistry exhibited a minimally invasive
phenotype, whereas only 8% of IDH-1 wild-type tumors exhibited
this phenotype37 (Figure 3). This suggests different invasive
behaviors between IDH-1–mutated and wild-type tumors. These
may explain the differences in survival seen with extended resection
of IDH-1–mutated tumors.15
FIGURE 3. An example of the diffusion tensor tissue signatures of 2 patients with glioblastomas. Both are 46-year-old men with
left frontal glioblastomas. Top, a patient with an isocitrate dehydrogenase-1 (IDH-1) mutation. There is little difference (,1
cm) between the p (isotropic) and q (anisotropic) components of the diffusion tensor, suggesting a minimally invasive phenotype.
Bottom, a patient who has an IDH-1 wild-type glioblastoma. There is clear evidence of a diffuse pattern of invasion.
IMAGING MARKERS OF IDH-1 MUTATIONS
CLINICAL NEUROSURGERY VOLUME 62 | NUMBER 1 | AUGUST 2015 | 169
Copyright © Congress of Neurological Surgeons. Unauthorized reproduction of this article is prohibited
CONCLUSION
IDH-1–mutated gliomas are an important subgroup of
gliomas with an improved prognosis. Imaging methods, partic-
ularly spectroscopic and diffusion, are able to identify this
subgroup. Further studies are required to prospectively assess
these biomarkers in a multicenter setting to allow their use in
routine clinical practice.
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